Discoveries in Chronic Kidney Disease

Discoveries in Chronic Kidney Disease

Source:

Heerspink HJL, et al. Abstract FR-OR51. Presented at: ASN Kidney Week; Nov. 2-7, 2021 (virtual meeting).

Disclosures: Heerspink reports commercial support for this presentation from AstraZeneca. Please see the study for all other authors' relevant financial disclosures.
November 23, 2021
1 min read
Save

Dapagliflozin significantly slows rate of kidney decline in patients with CKD

Source:

Heerspink HJL, et al. Abstract FR-OR51. Presented at: ASN Kidney Week; Nov. 2-7, 2021 (virtual meeting).

Disclosures: Heerspink reports commercial support for this presentation from AstraZeneca. Please see the study for all other authors' relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

For patients with chronic kidney disease, dapagliflozin slowed long-term decreases in the eGFR.

The total eGFR slope from randomization to the end of treatment supported dapagliflozin as compared with placebo, study author Hiddo J. L. Heerspink, PhD, PharmaD, a professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in the Netherlands, said during his presentation at ASN Kidney Week.

In patients with type 2 diabetes the mean difference between dapagliflozin and placebo was even greater.

"In both subgroups, dapagliflozin causes an acute decline in eGFR at week 2. The difference is slightly larger in patients with type 2 diabetes. In both subgroups, dapagliflozin slowed the rate of kidney function decline from week 2 until end of treatment" Heerspink said.

In age and sex subgroups, the effects of dapagliflozin were consistent, Heerspink said.

He noted, however, that previous analysis of clinical outcomes in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial by type 2 diabetes status has shown the effect of dapagliflozin on the primary and kidney-specific endpoints were the same, despite the difference in eGFR slope.

“The explanation is likely that dapagliflozin exerts a so-called proportional treatment effect, which means that the effect of dapagliflozin on eGFR slope is dependent on the underlying rate of renal function decline; with a larger, more pronounced effect in those with a faster progression,” said Heerspink.